Publications of Nina Kawelke

Altrock, E.; Sens, C.; Wuerfel, C.; Vasel, M.; Kawelke, N.; Dooley, S.; Sottile, J.; Nakchbandi, I.: Erratum to “Inhibition of fibronectin deposition improves experimental liver fibrosis” [J Hepatol 2015;62:625–633]. JOURNAL OF HEPATOLOGY 62 (6), pp. 1455 - 1456 (2015)

Altrock, E.; Sens, C.; Wuerfel, C.; Vasel, M.; Kawelke, N.; Dooley, S.; Sottile, J.; Nakchbandi, I.: Inhibition of fibronectin deposition improves experimental liver fibrosis. Journal of Hepatology 62 (3), pp. 625 - 633 (2015)

Wuerfel, C.; Hoffmann, C.; Kawelke, N.; Aszodi, A.; Nakchbandi, I.: Deletion of cdc42 in osteoblast progenitors leads to increased adipocyte differentiation and decreased bone formation. Bone 50 (Suppl. 1), p. S43 - S43 (2012)

Kawelke, N.; Vasel, M.; Sens, C.; von Au, A.; Dooley, S.; Nakchbandi, I. A.: Fibronectin Protects from Excessive Liver Fibrosis by Modulating the Availability of and Responsiveness of Stellate Cells to Active TGF-beta. PLoS ONE 6 (11), e28181, pp. [1] - [14] (2011)

Schmidt, S.; Nakchbandi, I.; Ruppert, R.; Kawelke, N.; Hess, M. W.; Pfaller, K.; Jurdic, P.; Fässler, R.; Moser, M.: Kindlin-3-mediated signaling from multiple integrin classes is required for osteoclast-mediated bone resorption. Journal of Cell Biology 192 (5), pp. 883 - 897 (2011)

Kawelke, N.; Vasel, M.; Nakchbandi, I.: FIBRONECTIN IN THE LIVER MODIFIES SEVERITY OF LIVER FIBROSIS. Journal of Hepatology 54 (Suppl. 1), p. 1040 - 1040 (2011)

Bentmann, A.; Kawelke, N.; Moss, D.; Zentgraf, H.; Bala, Y.; Berger, I.; Gasser, J. A.; Nakchbandi, I. A.: Circulating Fibronectin Affects Bone Matrix, Whereas Osteoblast Fibronectin Modulates Osteoblast Function. Journal of Bone and Mineral Research 25 (4), pp. 706 - 715 (2010)

Bentmann, A.; Kawelke, N.; Moss, D.; Nakchbandi, I.: Circulating Fibronectin Affects Bone Matrix. Journal of Bone and Mineral Research 23 (Suppl. Suppl. S), p. S163 - S163 (2008)

Kawelke, N.; Bentmann, A.; Hackl, N.; Hager, H. D.; Feick, P.; Geursen, A.; Singer, M. V.; Nakchbandi, I. A.: Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. Journal of Bone and Mineral Research 23 (8), pp. 1278 - 1286 (2008)

Bentmann, A.; Kawelke, N.; Gasser, J.; Nakchbandi, I. A.: Circulating plasma fibronectin is needed for a normal bone density. Calcified Tissue International 82 (Suppl. Suppl. 1), p. S97 - S97 (2008)

Bentmann, A.; Kawelke, N.; Moss, D.; Nakchbandi, I. A.: Osteoblast fibronectin affects their behavior in vivo. Calcified Tissue International 82 (Suppl. Suppl. 1), p. S97 - S97 (2008)

Kawelke, N.; Bentmann, A.; Hackl, N.; Nakchbandi, I. A.: Bone loss in patients with primary biliary cirrhosis is caused by a fibronectin isoform. Calcified Tissue International 82 (Suppl. Suppl. 1), p. S106 - S106 (2008)

Kawelke, N.; Nakchbandi, I.: Beta1 integrin on osteoblast progenitors affects bone formation and mineralization. In Bone, 50 (Suppl. 1), pp. S41 - S42. ELSEVIER SCIENCE INC, NEW YORK (2012)

Sens, C.; Kawelke, N.; Nakchbandi, I.: A fibronectin isoform containing the extra domain A (EDA) increases osteoblast differentiation and function. In Bone, 50 (Suppl. 1), pp. S74 - S75. ELSEVIER SCIENCE INC, NEW YORK (2012)

Sens, C.; von Au, A.; Kawelke, N.; Nakchbandi, I.: O-glycosylation in the variable region of fibronectin modulates osteoblast function in vitro and in vivo. In Bone, 50 (Suppl. 1), p. S74 - S74. ELSEVIER SCIENCE INC, NEW YORK (2012)

Kawelke, N.; Kraft, S.; Vasel, M.; Nakchbandi, I. A.: Beta1 integrin expression in osteoblast progenitors is required for bone formation. In Bone, 48 (Suppl. 2), p. S118 - S118. ELSEVIER SCIENCE INC, NEW YORK (2011)